Consistent with the effects on Jak2/Idh2-mutant–driven MPN in vivo, combination therapy reversed the aberrant transcriptional and metabolic abnormalities in JAK2/IDH2-mutant stem/progenitor cells. The gene discussed is JAK2; the disease is myeloproliferative disorder.